Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CCT303-406
i
Other names:
CCT-303-406, CCT303-406, CCT303-406 CAR modified autologous T cells, CCT303, CCT3-HER2-0406, CCT 303 406
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Exuma Biotech, Sunterra Biotech
Drug class:
HER2-targeted CAR-T immunotherapy
Related drugs:
‹
AU-101 (0)
AU-105 (0)
BPX-603 (0)
CART-HER-2 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HER2-Specific CAR T (0)
HypoSti.CAR-HER2 T (0)
MB-103 (0)
RB-312 (0)
RB-340 (0)
SC-CAR4BRAIN (0)
s (0)
SCRI-huCAR19v1 (0)
SCRI-huCAR19v2 (0)
SNC109 (0)
TGFBeta resistant HER2/EBV-CTLs (0)
TT16 (0)
AU-101 (0)
AU-105 (0)
BPX-603 (0)
CART-HER-2 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HER2-Specific CAR T (0)
HypoSti.CAR-HER2 T (0)
MB-103 (0)
RB-312 (0)
RB-340 (0)
SC-CAR4BRAIN (0)
s (0)
SCRI-huCAR19v1 (0)
SCRI-huCAR19v2 (0)
SNC109 (0)
TGFBeta resistant HER2/EBV-CTLs (0)
TT16 (0)
›
Associations
News
Trials
Filter by
Latest
25d
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Oct 2024
25 days ago
Enrollment closed • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
cyclophosphamide • CCT303-406
over2years
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
P1, N=15, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2022 --> Oct 2022
over 2 years ago
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
cyclophosphamide • CCT303-406
over4years
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
P1, N=15, Recruiting, Shanghai PerHum Therapeutics Co., Ltd.
over 4 years ago
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
CCT303-406
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login